Advice
following an abbreviated submission
darunavir, cobicistat, emtricitabine, tenofovir alafenamide (Symtuza®) is accepted for use within NHS Scotland.
Indication under review: the treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents (aged 12 years and older with body weight at least 40kg).
SMC has previously accepted darunavir/cobicistat (Rezolsta®) and emtrictabine/tenofovir alafenamide (Descovy®). Symtuza® (darunavir, cobicistat, emtricitabine, tenofovir alafenamide) provides a single-tablet alternative to Rezolsta® plus Descovy® at no additional cost.
Download detailed advice45KB (PDF)
Medicine details
- Medicine name:
- darunavir/cobicistat/emtricitabine/tenofovir alafenamide fumarate (Symtuza)
- SMC ID:
- 1290/18
- Indication:
- The treatment of human immunodeficiency virus type 1 (HIV-1) infection in adults and adolescents (aged 12 years and older with body weight at least 40kg).
- Pharmaceutical company
- Janssen-Cilag Ltd
- BNF chapter
- Infections
- Submission type
- Abbreviated
- Status
- Accepted
- Date advice published
- 15 January 2018